Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGKA | P23743 | 1/20 | 0.55 |
| ▸ | FAAH | O00519 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | CNR1 | P21554 | 1/20 | 0.50 |
| ▸ | CNR2 | P34972 | 1/20 | 0.50 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.49 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.49 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.49 |
| ▸ | PRKCA | P17252 | 1/20 | 0.49 |
| ▸ | NAAA | Q02083 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5482407 | 1.00 | DGKA (0.55) | DGKAFAAHALDH1A1CNR1CNR2 | |
| SCHEMBL1768207 | 1.00 | DGKA (0.55) | DGKAFAAHALDH1A1CNR1CNR2 | |
| SCHEMBL407730 | 1.00 | DGKA (0.55) | DGKAFAAHALDH1A1CNR1CNR2 | |
| SCHEMBL18662301 | 0.95 | ALDH1A1 (0.57) | DGKAFAAHALDH1A1CNR1CNR2 | |
| Phosphoric Acid SCHEMBL4261864 | 0.94 | LPAR1 (0.51) | DGKAFAAH | |
| SCHEMBL23121501 | 0.90 | NAAA (0.59) | NAAA | |
| SCHEMBL118318 | 0.90 | NAAA (0.59) | NAAA | |
| SCHEMBL114472 | 0.90 | NAAA (0.59) | NAAA | |
| SCHEMBL117824 | 0.90 | NAAA (0.59) | NAAA | |
| SCHEMBL23467113 | 0.90 | NAAA (0.59) | NAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 827 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112641667-B | High-stability transparent ceramide nanoemulsion gel and preparation and application thereof | 江苏瑞霆生物科技有限公司 | 2022-03-25 | — | — | CN | claimed |
| CN-112641667-A | High-stability transparent ceramide nanoemulsion gel and preparation and application thereof | 江苏瑞霆生物科技有限公司 | 2021-04-13 | — | — | CN | claimed |
| CN-112057406-A | Bicontinuous clear and thorough cleansing oil and preparation method thereof | 上海典雅生物科技有限公司 | 2020-12-11 | — | — | CN | claimed |
| US-10322078-B2 | Cosmetic composition containing 3-O-alkyl-L-ascorbic acid or salt thereof | AJINOMOTO CO., INC. (JP) | 2019-06-18 | — | — | US | claimed |
| EP-2868325-B1 | TRANSDERMAL CANCER ANTIGEN PEPTIDE PREPARATION | SUMITOMO DAINIPPON PHARMA CO LTD (JP) | 2017-11-01 | — | — | EP | claimed |
| EP-1633313-B1 | LIPID COMPOSITION AND SKIN CARE FORMULATION CONTAINING THE SAME | TAKASAGO PERFUMERY CO LTD (JP) | 2016-12-07 | — | — | EP | claimed |
| US-20160120803-A1 | NON-AEROSOL FOAMS FOR TOPICAL ADMINISTRATION | CONTRACT PHARMACEUTICALS LIMITED (CA) | 2016-05-05 | — | — | US | claimed |
| EP-3010487-A1 | NON-AEROSOL FOAMS FOR TOPICAL ADMINISTRATION | Contract Pharmaceuticals Limited (CA) | 2016-04-27 | — | — | EP | claimed |
| US-20150150975-A1 | TRANSDERMAL CANCER ANTIGEN PEPTIDE PREPARATION | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2015-06-04 | — | — | US | claimed |
| EP-2868325-A1 | TRANSDERMAL CANCER ANTIGEN PEPTIDE PREPARATION | Sumitomo Dainippon Pharma Co., Ltd. (JP) | 2015-05-06 | — | — | EP | claimed |
| WO-2014201541-A1 | NON-AEROSOL FOAMS FOR TOPICAL ADMINISTRATION | CONTRACT PHARMACEUTICALS LIMITED (CA) | 2014-12-24 | — | — | WO | claimed |
| US-8795421-B2 | W/O emulsion ink for inkjet | RISO KAGAKU CORPORATION (JP) | 2014-08-05 | — | — | US | claimed |
| US-20140044786-A1 | ONCE-WEEKLY ORAL ADMINISTRATION OF ARIPIPRAZOLE | ZYSIS LIMITED (GB) | 2014-02-13 | — | — | US | claimed |
| US-8242165-B2 | Mucoadhesive nanoparticles for cancer treatment | CREIGHTON UNIVERSITY (US) | 2012-08-14 | — | — | US | claimed |
| WO-2011050388-A1 | LIQUID CRYSTAL COMPOSITION AND METHOD OF USE | MONASH UNIVERSITY (AU) | 2011-05-05 | — | — | WO | claimed |
| US-20100323977-A9 | Mucoadhesive nanoparticles for cancer treatment | US ARMY, SECRETARY OF THE ARMY | 2010-12-23 | — | — | US | claimed |
| US-20090275526-A1 | Mucoadhesive nanoparticles for cancer treatment | DASH ALEKHA K | 2009-11-05 | — | — | US | claimed |
| JP-9208872-A | — | — | None | — | — | JP | disclosed |
| EP-0025302-A1 | Alpha-mono(methyl-branched alkyl) glyceryl ether and a skin care cosmetic composition containing the same | Kao Corporation (JP) | 1981-03-18 | — | — | EP | disclosed |
| JP-S5452734-A | CREAMY OR MILKY SKIN COSMETICS | KANEBO LTD | 1979-04-25 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275526-A1 | Mucoadhesive nanoparticles for cancer treatment | PNLIP, MUC1, LIPA | DGKA 146/4885FAAH 390/4885ALDH1A1 1964/4885 |
| US-20140044786-A1 | ONCE-WEEKLY ORAL ADMINISTRATION OF ARIPIPRAZOLE | CYP2A6, CYP2C19, CYP2D6 | DGKA 3386/4885FAAH 126/4885ALDH1A1 759/4885 |
| US-20150150975-A1 | TRANSDERMAL CANCER ANTIGEN PEPTIDE PREPARATION | TAP1, TAP2, MICA | DGKA 3660/4885FAAH 3738/4885ALDH1A1 4488/4885 |
| US-20100323977-A9 | Mucoadhesive nanoparticles for cancer treatment | PNLIP, MUC1, LIPA | DGKA 146/4885FAAH 390/4885ALDH1A1 1964/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.